{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:44:54Z","timestamp":1784763894816,"version":"3.55.0"},"reference-count":116,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"publisher","award":["PRIDE15\/10675146\/CANBIO, C20\/BM\/14582635, and C20\/BM\/14592342"],"award-info":[{"award-number":["PRIDE15\/10675146\/CANBIO, C20\/BM\/14582635, and C20\/BM\/14592342"]}],"id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["7.8506.19, H2020-MSCA-IF-2020: 101029602"],"award-info":[{"award-number":["7.8506.19, H2020-MSCA-IF-2020: 101029602"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hairy cell leukemia (HCL) is an incurable, rare lymphoproliferative hematological malignancy of mature B cAlthough first line therapy with purine analogues leads to positive results, almost half of HCL patients relapse after 5-10 years, and standard treatment may not be an option due to intolerance or refractoriness. Proliferation and survival of HCL cells is regulated by surrounding accessory cells and soluble signals present in the tumor microenvironment, which actively contributes to disease progression. <jats:italic>In vitro<\/jats:italic> studies show that different therapeutic approaches tested in HCL impact the tumor microenvironment, and that this milieu offers a protection affecting treatment efficacy. Herein we explore the effects of the tumor microenvironment to different approved and experimental therapeutic options for HCL. Dissecting the complex interactions between leukemia cells and their milieu will be essential to develop new targeted therapies for HCL patients.<\/jats:p>","DOI":"10.3389\/fonc.2023.1122699","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T06:07:09Z","timestamp":1678255629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives"],"prefix":"10.3389","volume":"13","author":[{"given":"Ernesto","family":"Gargiulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Moussay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Paggetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo El\u00edas","family":"Morande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26390","article-title":"Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment","volume":"97","author":"Troussard","year":"2022","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"US Lymphoid malignancy statistics by world health organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17201","article-title":"The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant","volume":"193","author":"Troussard","year":"2021","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V13.7.609.609","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"Bouroncle","year":"1958","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.V27.2.199.199","article-title":"\u201cHairy\u201d cells in blood in lymphoreticular neoplastic disease and \u201cflagellated\u201d cells of normal lymph nodes","volume":"27","author":"Schrek","year":"1966","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2011.02.014","article-title":"Chronic lymphocytic leukemia: the pathologist\u2019s view of lymph node microenvironment","volume":"28","author":"Ponzoni","year":"2011","journal-title":"Semin Diagn Pathol"},{"key":"B8","first-page":"57","article-title":"The immunophenotype of hairy cell leukemia (HCL). proposal for a scoring system to distinguish HCL from b-cell disorders with hairy or villous lymphocytes","volume":"14","author":"Matutes","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379339","article-title":"Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation","volume":"119","author":"Xi","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"238ra71","DOI":"10.1126\/scitranslmed.3008004","article-title":"Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia","volume":"6","author":"Chung","year":"2014","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(80)90066-1","article-title":"A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia","volume":"4","author":"Cawley","year":"1980","journal-title":"Leuk Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809058365","article-title":"BCL-2 immunohistochemical evaluation in b-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine","volume":"28","author":"Zaja","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00645","article-title":"BCL2-family dysregulation in b-cell malignancies: From gene expression regulation to a targeted therapy biomarker","volume":"8","author":"Tessoulin","year":"2018","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.05.014","article-title":"Cell death in the origin and treatment of cancer","volume":"78","author":"Strasser","year":"2020","journal-title":"Mol Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/cancers14051242","article-title":"Hairy cell leukemia patients have a normal life expectancy-a 35-year single-center experience and comparison with the general population","volume":"14","author":"Bohn","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1038\/bcj.2014.3","article-title":"Hairy cell leukemia: short review, today\u2019s recommendations and outlook","volume":"4","author":"Maevis","year":"2014","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-020-1325-9","article-title":"Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: A US population-retrospective claims analysis","volume":"15","author":"Epperla","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25264","article-title":"Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax","volume":"93","author":"Jain","year":"2018","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1608536","article-title":"Hairy cell leukemia: present and future directions","volume":"60","author":"Kreitman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1652589","article-title":"Novel therapeutics in hairy cell leukemia","volume":"12","author":"Sarvaria","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1068981","article-title":"Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders","volume":"12","author":"Maitre","year":"2022","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.598319","article-title":"In vitro sensitivity to venetoclax and microenvironment protection in hairy cell leukemia","volume":"11","author":"Vereertbrugghen","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the tumor microenvironment in mature b-cell lymphoid malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature b-cell malignancies: A target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.3945.bloodjournal88103945","article-title":"Endothelial interactions of hairy cells: the importance of alpha 4 beta 1 in the unusual tissue distribution of the disorder","volume":"88","author":"Vincent","year":"1996","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001723449","article-title":"Chemokine receptor expression in b-cell lymphoproliferative disorders","volume":"45","author":"Wong","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.4.880.880","article-title":"High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia","volume":"73","author":"Lindemann","year":"1989","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1760.1760","article-title":"Adhesion of hairy cells leukemia (HCL) cells to stromal cells can be inhibited by blocking VLA-4 integrins and CXCR4 chemokine receptors","volume":"118","author":"Sivina","year":"2011","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.3161","article-title":"Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia","volume":"96","author":"Aziz","year":"2000","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(87)80110-3","article-title":"Altered basement membrane structure of the spleen in hairy cell leukaemia. demonstration of laminin in hairy cells","volume":"182","author":"Karttunen","year":"1987","journal-title":"Pathol Res Pract"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/67.5.415","article-title":"Splenic pseudosinuses and hepatic angiomatous lesions. distinctive features of hairy cell leukemia","volume":"67","author":"Nanba","year":"1977","journal-title":"Am J Clin Pathol"},{"key":"B37","article-title":"T Lymphocyte function in hairy cell leukaemia","volume":"42","author":"Sabbe","year":"1980","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.251","article-title":"Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones","volume":"93","author":"van de Corput","year":"1999","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.9.3795.bloodjournal8793795","article-title":"Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia","volume":"87","author":"Kluin-Nelemans","year":"1996","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.9.3134.3134","article-title":"Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen","volume":"84","author":"Kluin-Nelemans","year":"1994","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-316737","article-title":"Evidence of canonical somatic hypermutation in hairy cell leukemia","volume":"117","author":"Arons","year":"2011","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0950","article-title":"Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch","volume":"104","author":"Forconi","year":"2004","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hon.975","article-title":"Hairy cell leukaemia: biological and clinical overview from immunogenetic insights","volume":"29","author":"Forconi","year":"2011","journal-title":"Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia b cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.8.4455","article-title":"Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human b cells","volume":"162","author":"Krzysiek","year":"1999","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ni735","article-title":"B cells and professional APCs recruit regulatory T cells via CCL4","volume":"2","author":"Bystry","year":"2001","journal-title":"Nat Immunol"},{"key":"B47","article-title":"Hairy cell leukemia. a therapeutical update","volume":"74","author":"Damasio","year":"1989","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2015.10.018","article-title":"Historical overview of hairy cell leukemia","volume":"28","author":"Andritsos","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.2.647","article-title":"Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion","volume":"100","author":"Baker","year":"2002","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood.V83.2.497.497","article-title":"The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells","volume":"83","author":"Burthem","year":"1994","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.3.873.873","article-title":"Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell\u2019s response to specific adhesive proteins","volume":"84","author":"Burthem","year":"1994","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100888","DOI":"10.1016\/j.blre.2021.100888","article-title":"Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues","volume":"51","author":"Kreitman","year":"2022","journal-title":"Blood Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.3390\/cells10123488","article-title":"Immunomodulatory effects associated with cladribine treatment","volume":"10","author":"Fissolo","year":"2021","journal-title":"Cells"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.11.027","article-title":"Cladribine exerts an immunomodulatory effect on human and murine dendritic cells","volume":"18","author":"Kraus","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129182","article-title":"Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells","volume":"10","author":"Korsen","year":"2015","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"19056","DOI":"10.1038\/s41598-021-98536-1","article-title":"Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers","volume":"11","author":"Koldej","year":"2021","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109068082","article-title":"Monocytes\/Macrophages stimulate hairy-cell proliferation","volume":"4","author":"Griffiths","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in b-cell hematologic malignancies: A review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04559-z","article-title":"Successful treatment of hairy cell leukemia variant with obinutuzumab","volume":"101","author":"Al-Sarayfi","year":"2022","journal-title":"Ann Hematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2520-y","article-title":"Obinutuzumab in multidrug-resistant hairy cell leukemia","volume":"95","author":"Bohn","year":"2016","journal-title":"Ann Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000303","article-title":"Glycoengineered, anti-CD20 monoclonal antibody GA101 in b-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab","volume":"186","author":"Bologna","year":"2011","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.121459","article-title":"Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study","volume":"100","author":"Osterborg","year":"2015","journal-title":"Haematologica"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.39","article-title":"CD40 stimulation sensitizes CLL cells to rituximab-induced cell death","volume":"25","author":"Jak","year":"2011","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in b-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-368209","article-title":"The BRAF V600E mutation in hairy cell leukemia and other mature b-cell neoplasms","volume":"119","author":"Arcaini","year":"2012","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013502","article-title":"How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors","volume":"139","author":"Falini","year":"2022","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016183","article-title":"Long term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy","volume":"140","author":"Handa","year":"2022","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"blood.2021013658","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia","author":"Kreitman","year":"2022","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.781800","article-title":"Pseudomonas exotoxin-based immunotoxins: Over three decades of efforts on targeting cancer cells with the toxin","volume":"11","author":"Havaei","year":"2021","journal-title":"Front Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2017.1284211","article-title":"Immunotoxins in cancer therapy: Review and update","volume":"36","author":"Akbari","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B76","first-page":"693","article-title":"Hairy cell leukemia, a b-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)","volume":"6","author":"Robbins","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3340.422k19_3340_3348","article-title":"Responses in refractory hairy cell leukemia to a recombinant immunotoxin","volume":"94","author":"Kreitman","year":"1999","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943354","article-title":"Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies","volume":"13","author":"Maharaj","year":"2022","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000187959.45803.0c","article-title":"Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2","volume":"29","author":"Attia","year":"2006","journal-title":"J Immunother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4919","article-title":"Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo","volume":"179","author":"Powell","year":"2007","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1320.h8001320_1320_1326","article-title":"Sensitization of b-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides","volume":"99","author":"Decker","year":"2002","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: a second-generation pseudomonas exotoxin a-based immunotherapy targeting CD22-expressing hematologic malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up","volume":"131","author":"Kreitman","year":"2018","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1714512115","article-title":"5-azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with moxetumomab pasudotox","volume":"115","author":"Muller","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08251.x","article-title":"Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia","volume":"150","author":"Mussai","year":"2010","journal-title":"Br J Haematol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.049155","article-title":"The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in b-cell lymphomas through CD22 upregulation and PKC-betaII depletion","volume":"97","author":"Biberacher","year":"2012","journal-title":"Haematologica"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206398","article-title":"Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways","volume":"22","author":"Kamiguti","year":"2003","journal-title":"Oncogene"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0087","article-title":"Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: Implications for CD22-directed immunotherapies","volume":"3","author":"Zheng","year":"2022","journal-title":"Blood Cancer Discovery"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1204523109","article-title":"Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy","volume":"109","author":"Wei","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-473744","article-title":"Trogocytosis of multiple b-cell surface markers by CD22 targeting with epratuzumab","volume":"122","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.803226","article-title":"Ibrutinib in chronic lymphocytic leukemia and b cell malignancies","volume":"55","author":"Brown","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12867","article-title":"The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and b cell receptor signalling: a new therapeutic approach","volume":"166","author":"Sivina","year":"2014","journal-title":"Br J Haematol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1239262","article-title":"Ibrutinib for relapsed refractory hairy cell leukemia variant","volume":"58","author":"Bohn","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809050927","article-title":"T-Cell dysfunction in hairy cell leukemia: An updated review","volume":"30","author":"Van De Corput","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"B99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-319-67577-0_4","article-title":"The role of tumor microenvironment in cancer immunotherapy","volume":"1036","author":"Frankel","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19540","article-title":"TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia","volume":"113","author":"Shehata","year":"2004","journal-title":"J Clin Invest"},{"key":"B102","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/cancers10060194","article-title":"TGF-beta in T cell biology: Implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"8706","DOI":"10.3390\/ijms22168706","article-title":"TGF-beta\/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive b cell lymphoma","volume":"22","author":"Noh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3874","article-title":"Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases","volume":"73","author":"Riese","year":"2013","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B106","article-title":"Serum interleukin-1 beta levels correlate with neoplastic bulk in hairy cell leukemia","volume":"5","author":"Cimino","year":"1991","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00539-3","article-title":"Venetoclax for the treatment of chronic lymphocytic leukemia","volume":"14","author":"Eradat","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting apoptosis in acute myeloid leukemia: Current status and future directions of BCL-2 inhibition with venetoclax and beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"10157","DOI":"10.3390\/ijms221810157","article-title":"BH3 mimetics in hematologic malignancies","volume":"22","author":"Klener","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/cancers14071772","article-title":"Transforming growth factor-beta orchestrates tumour and bystander cells in b-cell non-Hodgkin lymphoma","volume":"14","author":"Timmins","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax9340","article-title":"Stromal cell protein kinase c-beta inhibition enhances chemosensitivity in b cell malignancies and overcomes drug resistance","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13045-017-0435-x","article-title":"Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia","volume":"10","author":"Kashyap","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3390\/pharmaceutics14081541","article-title":"Recent advances in CXCL12\/CXCR4 antagonists and nano-based drug delivery systems for cancer therapy","volume":"14","author":"Zhao","year":"2022","journal-title":"Pharmaceutics"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1122699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T06:07:15Z","timestamp":1678255635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1122699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":116,"alternative-id":["10.3389\/fonc.2023.1122699"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1122699","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"article-number":"1122699"}}